Shattuck Labs, Inc. (STTK) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Shattuck Labs, Inc. is a preclinical-stage biotechnology company focused on developing treatments for inflammatory and immune-mediated diseases and cancer. The company's lead program is SL-325, a first-in-class death receptor 3 (DR3) antagonist antibody for inflammatory bowel disease (IBD). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $2.997 million | $0.686 million | $5.721 million | $0.943 million |
| Net Loss | $(16.675) million | $(27.541) million | $(56.731) million | $(69.611) million |
| Net Loss Per Share (Basic/Diluted) | $(0.33) | $(0.65) | $(1.12) | $(1.64) |
| Research & Development Expense | $16.313 million | $24.211 million | $51.816 million | $59.083 million |
| General & Administrative Expense | $4.604 million | $5.073 million | $14.831 million | $14.866 million |
| Cash, Cash Equivalents & Investments | $90.058 million (as of Sept 30, 2024) | |||
| Accumulated Deficit | $363.041 million (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Surge: Collaboration revenue increased 336.9% in Q3 and 506.7% YTD compared to 2023. This was driven by the Ono Pharmaceutical agreement, including the recognition of a $2.0 million option fee upon the mutual termination of the agreement in September 2024.
- Expense Reduction: R&D expenses decreased 32.6% in Q3 and 12.3% YTD. The reduction is attributed to decreased GMP manufacturing costs for the discontinued SL-172154 program and lower employee-related costs.
- Improved Loss Profile: Net loss narrowed significantly, decreasing 39.5% in Q3 and 18.5% YTD, primarily due to the revenue spike and cost reductions.
- Liquidity Position: Cash and cash equivalents decreased from $125.6 million at year-end 2023 to $43.8 million at Q3 2024, though total liquid assets (including investments) remain at $90.1 million.
Guidance, Outlook, and Material Events
- Strategic Restructuring: In October 2024, the company announced a restructuring plan to prioritize the DR3 program (SL-325). This includes the discontinuation of the SL-172154 clinical program following survival data readouts. Approximately 40% of the workforce was impacted.
- Restructuring Costs: The company expects to incur restructuring charges between $1.5 million and $1.75 million in Q4 2024, primarily for employee severance.
- Collaboration Termination: The Ono Pharmaceutical agreement was mutually terminated on September 30, 2024. A $1.6 million prepayment received in August 2024 was refunded in Q4 2024.
- Liquidity Outlook: Management believes current cash, cash equivalents, and investments ($90.1 million) are sufficient to fund operations into 2027.
- Risk Factors: The company remains preclinical with no approved products. Future success depends on the development of SL-325, regulatory approvals, and the ability to raise additional capital if needed.
Key Investor Verification Points
- Restructuring Execution: Verify the actual Q4 2024 restructuring charges and the timeline for the reduction in force.
- SL-325 Progress: Monitor the timeline for the Investigational New Drug (IND) application filing, currently expected in Q3 2025.
- Cash Burn Rate: Assess the post-restructuring operating expense run rate to validate the "into 2027" liquidity runway.
- Refund Impact: Confirm the cash outflow impact of the $1.6 million Ono prepayment refund in Q4 2024.
- Capital Needs: Evaluate the potential need for future equity or debt financing given the preclinical stage and lack of product revenue.